+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Prader-Willi Syndrome Therapeutics Market 2018-2022 - Product Image

Global Prader-Willi Syndrome Therapeutics Market 2018-2022

  • ID: 4718438
  • Report
  • November 2018
  • Region: Global
  • 102 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novartis
  • Novo Nordisk
  • Pfizer
  • MORE
About this market

The number of pipeline molecules in the global PWS therapeutics market is increasing at a good phase. The pipeline has many promising therapeutics agents, which are expected to boost the market growth. According to industry experts, approximately 15 therapeutics, are under different stages of development in the pipeline. The number of clinical trials is continuously increasing for the development of therapeutics for the treatment of PWS. This is expected to drive them market growth during our forecast period. These increasing number of special drug designations from regulatory bodies is expected to drive the market at a CAGR of close to 5% between 2018-2022.

Market Overview

Special drug designations

PWS is a rare disorder, and its prevalence rate is usually lower compared with other mainstream indications. Therefore, drug manufactures often hesitate to invest large amounts in drug discovery R&D. Therefore, regulatory bodies grant special drug designations, which will help in further development if the drug.

Lack of awareness of PWS

The sales of potential products are difficult to attain due to awareness issues. Though effective treatments available, individual attitudes, beliefs, poor treatment adherence and inadequate communication between clinicians and patients about PWS hinder the market growth.

For the detailed list of factors that will drive and challenge the growth of the Prader Willi syndrome therapeutics market during the 2018-2022, view the full report.

Competitive Landscape

This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies. The vendors in the market forming strategic alliances by acquiring businesses gain competitive advantages. The market is formatting alliances between public and private stakeholders. The companies constantly focusing improving their market positions, the competitive environment among the players is quite intense.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novartis
  • Novo Nordisk
  • Pfizer
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: PIPELINE LANDSCAPE

PART 08: MARKET SEGMENTATION BY PRODUCT
  • Segmentation by product
  • Comparison by product
  • Recombinant growth hormones - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by product
  • CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS
  • Strong pipeline
  • Increasing strategic alliances
  • Use of advanced technologies for diagnosis and treatment of PWS
PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Eli Lilly and Company
  • Novartis
  • Novo Nordisk
  • Pfizer
PART 15: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global rare disease therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 09: Global - Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase 2017-2018
Exhibit 19: Key clinical trial candidates for treatment of PWS
Exhibit 20: Global PWS therapeutics market by product 2017-2022 (%)
Exhibit 21: Comparison by product
Exhibit 22: Recombinant growth hormones - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Recombinant growth hormones - Year-over-year growth 2018-2022 (%)
Exhibit 24: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Others - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: Eli Lilly and Company - Overview
Exhibit 46: Eli Lilly and Company - Business segments
Exhibit 47: Eli Lilly and Company - Organizational developments
Exhibit 48: Eli Lilly and Company - Geographic focus
Exhibit 49: Eli Lilly and Company - Segment focus
Exhibit 50: Eli Lilly and Company - Key offerings
Exhibit 51: Eli Lilly and Company - Key customers
Exhibit 52: Novartis - Overview
Exhibit 53: Novartis - Business segments
Exhibit 54: Novartis - Organizational developments
Exhibit 55: Novartis - Geographic focus
Exhibit 56: Novartis - Segment focus
Exhibit 57: Novartis: Key offerings
Exhibit 58: Novartis - Key customers
Exhibit 59: Novo Nordisk - Overview
Exhibit 60: Novo Nordisk - Business segments
Exhibit 61: Novo Nordisk - Organizational developments
Exhibit 62: Novo Nordisk - Geographic focus
Exhibit 63: Novo Nordisk - Segment focus
Exhibit 64: Novo Nordisk - Key offerings
Exhibit 65: Novo Nordisk - Key customers
Exhibit 66: Pfizer - Overview
Exhibit 67: Pfizer - Business segments
Exhibit 68: Pfizer - Organizational developments
Exhibit 69: Pfizer - Geographic focus
Exhibit 70: Pfizer - Segment focus
Exhibit 71: Pfizer - Key offerings
Exhibit 72: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Eli Lilly
  • Novartis
  • Novo Nordisk
  • Pfizer
  • MORE
Global Prader-Willi Syndrome Therapeutics Market 2018-2022

The author of the report recognizes the following companies as the key players in the global Prader-Willi syndrome therapeutics market: Eli Lilly and company, Novartis, Novo Nordisk and Pfizer.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the pipeline has many promising therapeutics agents, which are expected to boost the market growth.

According to the report, one of the major drivers for this market is the increasing number of special drug designations from the regulatory bodies is expected to drive the market growth.

Further, the report states that one of the major factors hindering the growth of this market is the stringent government regulations for marketing approval are excepted to hamper the growth of the market during the forecast period.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Eli Lilly
  • Novartis
  • Novo Nordisk
  • Pfizer
Note: Product cover images may vary from those shown
Adroll
adroll